BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: O'Tuathaigh CMP, Moran PM, Zhen XC, Waddington JL. Translating advances in the molecular basis of schizophrenia into novel cognitive treatment strategies. Br J Pharmacol 2017;174:3173-90. [PMID: 28667666 DOI: 10.1111/bph.13938] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
Number Citing Articles
1 Jiao S, Cao T, Cai H. Peripheral biomarkers of treatment-resistant schizophrenia: Genetic, inflammation and stress perspectives. Front Pharmacol 2022;13:1005702. [DOI: 10.3389/fphar.2022.1005702] [Reference Citation Analysis]
2 Pacheco J, Garvey MA, Sarampote CS, Cohen ED, Murphy ER, Friedman-Hill SR. Annual Research Review: The contributions of the RDoC research framework on understanding the neurodevelopmental origins, progression and treatment of mental illnesses. J Child Psychol Psychiatry 2022. [PMID: 34979592 DOI: 10.1111/jcpp.13543] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 9.0] [Reference Citation Analysis]
3 Salami M. Gut Microbiota in Brain diseases. Comprehensive Gut Microbiota 2022. [DOI: 10.1016/b978-0-12-819265-8.00040-1] [Reference Citation Analysis]
4 Sanford N, Woodward TS. Functional Delineation of Prefrontal Networks Underlying Working Memory in Schizophrenia: A Cross-data-set Examination. J Cogn Neurosci 2021;33:1880-908. [PMID: 34375420 DOI: 10.1162/jocn_a_01726] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Fyfe TJ, Scammells PJ, Lane JR, Capuano B. Enantioenriched Positive Allosteric Modulators Display Distinct Pharmacology at the Dopamine D1 Receptor. Molecules 2021;26:3799. [PMID: 34206465 DOI: 10.3390/molecules26133799] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Sotiropoulos MG, Poulogiannopoulou E, Delis F, Dalla C, Antoniou K, Kokras N. Innovative screening models for the discovery of new schizophrenia drug therapies: an integrated approach. Expert Opin Drug Discov 2021;16:791-806. [PMID: 33467920 DOI: 10.1080/17460441.2021.1877657] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
7 Okasha TA, Hussein H, Shorub E, Nagi H, Moustafa AA, El-serafi D. Cognitive dysfunction among inpatients and outpatients with schizophrenia: relationship to positive and negative symptoms. Middle East Curr Psychiatry 2020;27:58. [DOI: 10.1186/s43045-020-00062-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
8 Nani JV, Dal Mas C, Yonamine CM, Ota VK, Noto C, Belangero SI, Mari JJ, Bressan R, Cordeiro Q, Gadelha A, Hayashi MAF. A study in first-episode psychosis patients: does angiotensin I-converting enzyme (ACE) activity associated with genotype predict symptoms severity reductions after treatment with the atypical antipsychotic risperidone? Int J Neuropsychopharmacol 2020:pyaa050. [PMID: 32696960 DOI: 10.1093/ijnp/pyaa050] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Bruno A, Zoccali RA, Troili GM, Scala L, Pandolfo G, Cedro C, Mento C, Santoro V, Spina E, Muscatello MRA. Vortioxetine on Cognition in Schizophrenia: A Pilot Study. J Clin Psychopharmacol 2020;40:381-5. [DOI: 10.1097/jcp.0000000000001242] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
10 Matsumura K, Seiriki K, Okada S, Nagase M, Ayabe S, Yamada I, Furuse T, Shibuya H, Yasuda Y, Yamamori H, Fujimoto M, Nagayasu K, Yamamoto K, Kitagawa K, Miura H, Gotoda-Nishimura N, Igarashi H, Hayashida M, Baba M, Kondo M, Hasebe S, Ueshima K, Kasai A, Ago Y, Hayata-Takano A, Shintani N, Iguchi T, Sato M, Yamaguchi S, Tamura M, Wakana S, Yoshiki A, Watabe AM, Okano H, Takuma K, Hashimoto R, Hashimoto H, Nakazawa T. Pathogenic POGZ mutation causes impaired cortical development and reversible autism-like phenotypes. Nat Commun 2020;11:859. [PMID: 32103003 DOI: 10.1038/s41467-020-14697-z] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 20.0] [Reference Citation Analysis]
11 Penadés R, Bosia M, Catalán R, Spangaro M, García-Rizo C, Amoretti S, Bioque M, Bernardo M. The role of genetics in cognitive remediation in schizophrenia: A systematic review. Schizophr Res Cogn 2020;19:100146. [PMID: 31832337 DOI: 10.1016/j.scog.2019.100146] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
12 Nikiforuk A. Assessment of cognitive functions in animal models of schizophrenia. Pharmacological Reports 2018;70:639-49. [DOI: 10.1016/j.pharep.2018.01.009] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
13 Bailey SJ, Neill JC, Moran PM. Pharmacology of cognition: a panacea for neuropsychiatric disease? Br J Pharmacol 2017;174:3133-5. [PMID: 28901012 DOI: 10.1111/bph.13956] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
14 O'Tuathaigh CMP, Moran PM, Zhen XC, Waddington JL. Translating advances in the molecular basis of schizophrenia into novel cognitive treatment strategies. Br J Pharmacol 2017;174:3173-90. [PMID: 28667666 DOI: 10.1111/bph.13938] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]